News
Bristol Myers Squibb (BMS) and Bain Capital have created an independent biopharmaceutical company to develop immunology ...
Bristol-Myers Squibb offers strong cash flow, solid growth, and a high yield despite pricing pressure and pipeline risks.
Zacks.com on MSN3d
BMY Stock Trades Near 52-Week Low: Time to Buy or Sell?
Detailed price information for Bristol-Myers Squibb Company (BMY-N) from The Globe and Mail including charting and trades.
Zacks Investment Research on MSN4d
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Bristol Myers Squibb (BMY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to ...
Conference ID: BAIN All participants will need to reference “Bain Capital Specialty Finance - Second Quarter Ended June 30, 2025 Earnings Conference Call” once connected with the operator.
American private investment firm Bain Capital is on the verge of acquiring a significant stake in Manappuram Finance, one of Kerala’s leading gold loan providers, in a deal valued at ...
Review the current Bristol-Myers Squibb Co (BMY:XNYS) growth, profitability and efficiency, financial health, and cash flow key metrics to decide if BMY is the best investment for you.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback